Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
rafeykeith

Tetraphase Pharmaceuticals Reports First-quarter 2015 Financial Results - Yahoo Finance

Nobody wants to foot the bill for new antibiotics: Norwegian study -- ScienceDaily

Macdonald continued: "We were also pleased to have raised an additional $173 million through a public offering which will allow us to prepare for commercial launch of eravacycline." First-Quarter 2015 Financial Results For the first quarter of 2015, Tetraphase reported a net loss of $21.0 million, or $0.66 per share, compared to a net loss of $13.5 million, or $0.53 per share, for the same period in 2014. Revenues during the first quarter of 2015 were $3.0 million compared to $2.5 million for the same period in 2014. Revenues for each period consisted of contract and grant revenue under the Company's U.S. government awards for the development of Tetraphase compounds for the treatment of diseases caused by bacterial biothreat pathogens and for certain infections caused by life-threatening multidrug-resistant bacteria. Research and development (R&D) expenses for the first quarter of 2015 were $18.9 million compared to $12.5 million for the same period in 2014. The increase in R&D expenses was primarily due to drug manufacturing and nonclinical activities in support of the planned NDA filing for eravacycline, as well as an increase in clinical costs associated with our ongoing phase 3 program for eravacycline and an increase in stock-based compensation.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/tetraphase-pharmaceuticals-reports-first-quarter-200100309.html

Steigedal, Director of the Norwegian University of Science and Technology's (NTNU) Strategic Research Area on Health, is also head of the Norwegian section of a large EU project on the development of new antibiotics. He is busy. More people die from antibiotic-resistant bacteria than from traffic accidents in Europe. About two million people die of tuberculosis every year. If antibiotics can no longer kill bacteria, a simple urinary tract infection can be fatal. A ticking time bomb Antibiotic-resistant bacteria are like a ticking time bomb. The world needs new antibiotics.
For the original version including any supplementary images or video, visit http://www.sciencedaily.com/releases/2015/05/150507081950.htm

Molecular homing beacon redirects human antibodies to fight pathogenic bacteria -- ScienceDaily

The study offers the first proof-of-concept that Alphamers have the potential to specifically redirect pre-existing antibodies to bacteria and rapidly activate an antibacterial immune response. "Our next step is to test Alphamers in animal models of infection with multidrug-resistant bacteria that pose a public health threat, such as MRSA," said first author Sascha Kristian, PhD, visiting research scholar at UC San Diego and associate research director at Altermune Technologies, a company Mullis founded to develop Alphamers into unique therapeutics. "Meanwhile, we'll also be tweaking the Alphamer to make it more potent and more resistant to degradation by the body." If Alphamers continue to show promise, natural mrsa cures researchers might be able to apply the same concept to attack any type of bacteria or virus, or perhaps even cancer cells. "We're picturing a future in which doctors have a case full of pathogen-specific Alphamers at their disposal," Nizet said. "They see an infected patient, identify the causative bacteria and pull out the appropriate Alphamer to instantly enlist the support of the immune system in curing the infection." An animation of the Alphamer technology is available at: https://youtu.be/5cfxhu3YqGs Story Source: The above story is based on materials provided by University of California, San Diego Health Sciences . The original article was written by Heather Buschman. Note: Materials may be edited for content and length.
For the original version including any supplementary images or video, visit http://www.sciencedaily.com/releases/2015/05/150506140444.htm

mrsa urine infection style="clear:both">Dipexium Pharmaceuticals to Hold First Quarter 2015 Financial Results Conference Call on Thursday, May 14, 2015, at 8:30 a.m. ET - Yahoo Finance

ET Dipexium Pharmaceuticals, Inc. May 7, 2015 8:00 AM Content preferences Done NEW YORK, May 7, 2015 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. ( DPRX ) will release its financial results for the quarter ended March 31, 2015, on Thursday, May 14, 2015 at 7:30 a.m. ET. The announcement will be followed by a conference call at 8:30 a.m. ET during which Dipexium management will discuss these results, recent developments and answer questions.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/dipexium-pharmaceuticals-hold-first-quarter-120000599.html

Does ISIS Have Any More Guys in the U.S.? : Discovery News

This is especially true in developing nations whose populations are generally younger. "A new outbreak in India or South Africa, for example, would be beyond terrible," said Tara Smith, an assistant professor of epidemiology at the University of Iowa. Centers for Disease Control View Caption + Resistant Bacteria Diseases that have been historically treated with antibiotics are good candidates for biological weapons because many strains have become resistant to the antibiotics.
For the original version including any supplementary images or video, visit http://news.discovery.com/human/life/does-isis-have-any-more-guys-in-the-u-s-150506.htm

Don't be the product, buy the product!

Schweinderl